Serious infectious diseases are spreading with unprecedented speed in our interconnected world.
Shionogi continues to discover leading drugs for bacterial, fungal and viral infections through our expertise in biomedical research and small molecule drug discovery. As part of the Global Health Innovative Technology Fund, a public-private partnership, our scientists are also working with strategic partners to research therapies for the treatment of patients with multi-drug-resistant tuberculosis and neglected tropical diseases.
Additionally, we are working to develop efficacious pharmaceutical products quickly and safely for the treatment of severe pain. These products include non-opioid analgesics with new mechanisms of action that could expand treatment options for patients with chronic pain.
Our research into cutting-edge medical technologies enables Shionogi to help create platforms for discovery in new development areas. These high-need areas include obesity, geriatric metabolic disease, oncology, immunology and the growing global health threat of Alzheimer’s disease.
To advance this innovation, Shionogi researchers pursue discovery through partnerships with leading universities and strategic alliances. By collaborating with world-class partners, Shionogi seeks to bring therapies to patients around the world who have limited or no treatment options for their serious, unmet medical needs.